A 52-year-old man with hypertension and chronic kidney disease (stage 3b) is prescribed either a calcium channel blocker (CCB) or a beta-blocker. Which single feature most reliably distinguishes the renal and metabolic effects of these two drug classes?

Explanation

## Metabolic and Renal Distinction: CCBs vs. Beta-Blockers ### Comparative Pharmacology **Key Point:** Calcium channel blockers and beta-blockers differ significantly in their metabolic effects, particularly in patients with chronic kidney disease and diabetes. | Feature | Calcium Channel Blockers | Beta-Blockers | |---------|-------------------------|---------------| | **Renal Function** | Preserve / improve GFR | Preserve GFR | | **Glucose Metabolism** | Neutral or improve | Worsen (mask hypoglycemia, ↑ glucose) | | **Lipid Profile** | Neutral | Worsen (↑ triglycerides, ↓ HDL) | | **Proteinuria Reduction** | Minimal | Modest (non-selective) | | **Preferred in Diabetes + HTN** | Yes (first-line) | No (second-line) | | **Preferred in CKD** | Yes | Acceptable if no diabetes | ### Why the Correct Answer is Correct **High-Yield:** Beta-blockers (especially non-selective agents) impair glucose metabolism, increase triglycerides, and lower HDL cholesterol. This metabolic penalty is particularly problematic in patients with CKD and diabetes, who are already at high cardiovascular and renal risk. CCBs, by contrast, are metabolically neutral or even favorable — they do not adversely affect glucose or lipid homeostasis. ### Clinical Pearl: Renal Protection Neither class directly damages the kidney at therapeutic doses. However, **ACE inhibitors and ARBs** are superior for renal protection in diabetic and non-diabetic CKD because they reduce intraglomerular pressure by dilating the efferent arteriole. CCBs dilate both afferent and efferent arterioles, preserving GFR but offering less glomerular protection. Beta-blockers have no direct renal benefit. ### Mechanism of Metabolic Harm (Beta-Blockers) 1. **Glucose:** Beta-blockade reduces hepatic glucose output and impairs insulin secretion; also masks hypoglycemic symptoms (especially non-selective agents). 2. **Lipids:** Non-selective beta-blockers increase VLDL and triglycerides; reduce HDL. 3. **Sexual Function:** Beta-blockers may cause erectile dysfunction (sympathetic inhibition). **Mnemonic:** **ABCDE** of beta-blocker side effects — **A**irway (asthma/COPD), **B**radycardia, **C**old extremities, **D**iabetes (worsen), **E**rectile dysfunction. ### Why CCBs Are Preferred in This Scenario In a patient with CKD stage 3b and hypertension, a CCB is preferred over a non-selective beta-blocker because: - Preserves renal function (does not reduce GFR). - No adverse metabolic effects. - If the patient has concurrent diabetes, CCBs avoid the glucose and lipid penalties of beta-blockers. [cite:Harrison 21e Ch 297]